Regulus Therapeutics (RGLS) Surges Over 150% on Following Positive Interim Results for RG-101 in HCV
Tweet Send to a Friend
Regulus Therapeutics (NASDAQ: RGLS) is surging 162% in pre-open trade after the company announced that it has demonstrated human proof-of-concept ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
